title: Efficacy and Safety of an Aclidinium Bromide Treatment for 12 Weeks or Longer in Patients with Moderate-To-Severe COPD: A Meta-Analysis.
abstract: Bronchodilators are commonly used to manage patients with stable chronic obstructive pulmonary disease (COPD). This meta-analysis assessed the efficacy of aclidinium bromide with respect to clinical events, health-related quality of life and symptom scales, pulmonary function, and safety among patients with stable COPD.
  
  
  
  A comprehensive search of MEDLINE, EMBASE, CINAHL and the Cochrane Library databases was undertaken to identify randomized controlled trials (RCTs) that compared aclidinium with placebo, treatment over at least 12 weeks. Trials were measured using either odds ratios (OR) or mean differences (MD) with 95% confidence intervals (CI).
  
  
  
  Seven studies, containing 7001 patients, were included in this meta-analysis. Compared with placebo, aclidinium bromide reduced the incidence of exacerbation-related hospitalizations (OR 0.64; 95% CI 0.47 to 0.89) and improved quality of life as measured by a lower total George's Respiratory Questionnaire [SGRQ] score (MD -2.34; 95% CI -3.18 to -1.51) and attenuated dyspnea symptom as assessed by changes in the Transitional Dyspnea Index [TDI] (MD 0.76; 95% CI 0.43 to 1.10). Similar changes were observed with regard to trough FEV1 and FVC and peak FEV1 and FVC. No significant differences were observed with regard to all-cause mortality, COPD exacerbations, non-fatal serious adverse events or cardiac adverse events.
  
  
  
  Aclidinium reduced the incidence of exacerbation-related hospitalizations and improved quality of life, COPD symptoms and pulmonary function. In addition, aclidinium did not increase the incidence of non-fatal serious adverse events, cardiac adverse events, or COPD exacerbations and was not associated with increased mortality.
authors: a Department of Gerontology and Respiratory Diseases, Xiangya Hospital , Central South University , Changsha , Hunan , P.R. China.
authors: Yong
authors: Y
authors: Zou
authors: a Department of Gerontology and Respiratory Diseases, Xiangya Hospital , Central South University , Changsha , Hunan , P.R. China.
authors: Jian
authors: J
authors: Xiao
authors: a Department of Gerontology and Respiratory Diseases, Xiangya Hospital , Central South University , Changsha , Hunan , P.R. China.
authors: Dan Hui
authors: DH
authors: Yang
authors: b Thyroid Tumour Internal Medicine Department , Cancer Hospital affiliated to Xiangya School of Medicine, Central South University , Changsha , Hunan , P.R. China.
authors: Jun
authors: J
authors: Li
authors: a Department of Gerontology and Respiratory Diseases, Xiangya Hospital , Central South University , Changsha , Hunan , P.R. China.
authors: Qiong
authors: Q
authors: Chen
mesh_terms: D002423:Cause of Death; D018450:Disease Progression; D004417:Dyspnea / Q000209:etiology; D005541:Forced Expiratory Volume; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D009026:Mortality; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D029424:Pulmonary Disease, Chronic Obstructive / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D012720:Severity of Illness Index; D011795:Surveys and Questionnaires; D016896:Treatment Outcome; D014326:Tropanes / Q000627:therapeutic use*; D014797:Vital Capacity
chemical_list: D018727:Muscarinic Antagonists; D014326:Tropanes; C542859:aclidinium bromide
keywords: COPD; aclidinium bromide; efficacy; meta-analysis; safety